You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDarifenacin
Accession NumberDB00496  (APRD00903)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionDarifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin works by blocking the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions. It thereby decreases the urgency to urinate. It should not be used in people with urinary retention. It is not known whether this selectivity for the M3 receptor translates into any clinical advantage when treating symptoms of overactive bladder syndrome.
Structure
Thumb
Synonyms
(S)-1-(2-(2,3-dihydro-5-Benzofuranyl)ethyl)-alpha,alpha-diphenyl-3-pyrrolidineacetamide
Darifenacin
Darifenacina
Darifénacine
Darifenacinum
External Identifiers
  • UK 88525
  • UK 88525-04
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DarifenacinTablet, extended release7.5 mg/1OralActavis Pharma, Inc.2016-03-15Not applicableUs
DarifenacinTablet, extended release15 mg/1OralActavis Pharma, Inc.2016-03-15Not applicableUs
EnablexTablet, extended release7.5 mgOralMerus Labs Luxco S. A R.L.2006-04-06Not applicableCanada
EnablexTablet, extended release7.5 mg/1OralWarner Chilcott (US), LLC2004-12-22Not applicableUs
EnablexTablet, extended release7.5 mg/1OralPhysicians Total Care, Inc.2006-11-06Not applicableUs
EnablexTablet, extended release15 mgOralMerus Labs Luxco S. A R.L.2006-04-06Not applicableCanada
EnablexTablet, extended release15 mg/1OralWarner Chilcott (US), LLC2004-12-22Not applicableUs
EnablexTablet, extended release15 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-05Not applicableUs
EnablexTablet, extended release15 mg/1OralPhysicians Total Care, Inc.2005-07-20Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-darifenacinTablet, extended release15 mgOralApotex IncNot applicableNot applicableCanada
Apo-darifenacinTablet, extended release7.5 mgOralApotex IncNot applicableNot applicableCanada
DarifenacinTablet, extended release15 mg/1OralCipla USA Inc.2016-09-01Not applicableUs
DarifenacinTablet, extended release15 mg/1OralTorrent Pharmaceuticals Limited2016-11-18Not applicableUs
DarifenacinTablet, film coated, extended release7.5 mg/1OralAurobindo Pharma Limited2016-09-19Not applicableUs
DarifenacinTablet, extended release7.5 mg/1OralJubilant Cadista Pharmaceuticals Inc.2016-10-12Not applicableUs
DarifenacinTablet, film coated, extended release15 mg/1OralAurobindo Pharma Limited2016-09-19Not applicableUs
DarifenacinTablet, extended release15 mg/1OralJubilant Cadista Pharmaceuticals Inc.2016-10-12Not applicableUs
DarifenacinTablet, extended release7.5 mg/1OralCipla USA Inc.2016-09-01Not applicableUs
DarifenacinTablet, extended release7.5 mg/1OralTorrent Pharmaceuticals Limited2016-11-18Not applicableUs
Darifenacin Hydrobromide Extended-releaseTablet, extended release7.5 mg/1OralPar Pharmaceutical2016-03-15Not applicableUs
Darifenacin Hydrobromide Extended-releaseTablet, extended release15 mg/1OralPar Pharmaceutical2016-03-15Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EmselexNovartis
XelenaDr. Reddy's
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Darifenacin Hydrobromide
ThumbNot applicableDBSALT001041
Categories
UNIIAPG9819VLM
CAS number133099-04-4
WeightAverage: 426.55
Monoisotopic: 426.230728214
Chemical FormulaC28H30N2O2
InChI KeyHXGBXQDTNZMWGS-RUZDIDTESA-N
InChI
InChI=1S/C28H30N2O2/c29-27(31)28(23-7-3-1-4-8-23,24-9-5-2-6-10-24)25-14-17-30(20-25)16-13-21-11-12-26-22(19-21)15-18-32-26/h1-12,19,25H,13-18,20H2,(H2,29,31)/t25-/m1/s1
IUPAC Name
2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide
SMILES
NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1
Pharmacology
IndicationFor the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.
Structured Indications
PharmacodynamicsDarifenacin is a competitive muscarinic receptor antagonist. In vitro studies using human recombinant muscarinic receptor subtypes show that darifenacin has greater affinity for the M3 receptor than for the other known muscarinic receptors (9 and 12-fold greater affinity for M3 compared to M1 and M5, respectively, and 59-fold greater affinity for M3 compared to both M2 and M4). Muscarinic receptors play an important role in several major cholinergically mediated functions, including contractions of the urinary bladder smooth muscle and stimulation of salivary secretion. Adverse drug effects such as dry mouth, constipation and abnormal vision may be mediated through effects on M3 receptors in these organs.
Mechanism of actionDarifenacin selectively antagonizes the muscarinic M3 receptor. M3 receptors are involved in contraction of human bladder and gastrointestinal smooth muscle, saliva production, and iris sphincter function.
TargetKindPharmacological actionActionsOrganismUniProt ID
Muscarinic acetylcholine receptor M3Proteinyes
antagonist
HumanP20309 details
Muscarinic acetylcholine receptor M1Proteinunknown
antagonist
HumanP11229 details
Muscarinic acetylcholine receptor M2Proteinunknown
antagonist
HumanP08172 details
Muscarinic acetylcholine receptor M4Proteinunknown
antagonist
HumanP08173 details
Muscarinic acetylcholine receptor M5Proteinunknown
antagonist
HumanP08912 details
Related Articles
AbsorptionThe mean oral bioavailability at steady state is estimated to be 15% and 19% for 7.5 mg and 15 mg tablets, respectively.
Volume of distribution
  • 163 L
Protein bindingDarifenacin is approximately 98% bound to plasma proteins (primarily to alpha-1-acid-glycoprotein).
Metabolism

Hepatic. Primarily mediated by the cytochrome P450 enzymes CYP2D6 and CYP3A4.

Route of eliminationNot Available
Half lifeThe elimination half-life of darifenacin following chronic dosing is approximately 13-19 hours.
Clearance
  • 40 L/h [extensive metabolizers]
  • 32 L/h [poor metabolizers]
ToxicityOverdosage can potentially result in severe central anticholinergic effects.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Darifenacin can be decreased when used in combination with 1,10-Phenanthroline.Experimental
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Darifenacin.Experimental, Illicit
AbirateroneThe serum concentration of Darifenacin can be increased when it is combined with Abiraterone.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Darifenacin.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Darifenacin.Approved
AclidiniumAclidinium may increase the anticholinergic activities of Darifenacin.Approved
AjmalineThe metabolism of Ajmaline can be decreased when combined with Darifenacin.Approved
AlfentanilThe risk or severity of adverse effects can be increased when Darifenacin is combined with Alfentanil.Approved, Illicit
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Darifenacin.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Darifenacin.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Darifenacin is combined with Alphacetylmethadol.Experimental, Illicit
AlprenololThe metabolism of Alprenolol can be decreased when combined with Darifenacin.Approved, Withdrawn
AmbenoniumThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Ambenonium.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Darifenacin.Approved, Withdrawn
AmiodaroneThe metabolism of Darifenacin can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Darifenacin.Approved
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Darifenacin.Approved
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Darifenacin.Approved, Illicit
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Darifenacin.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Darifenacin.Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Darifenacin is combined with Anisotropine Methylbromide.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Darifenacin.Approved
AprepitantThe serum concentration of Darifenacin can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Darifenacin.Approved
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Darifenacin.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Darifenacin.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Darifenacin.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Darifenacin.Approved, Withdrawn
AtazanavirThe metabolism of Darifenacin can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Darifenacin can be decreased when combined with Atomoxetine.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Darifenacin is combined with Atracurium besylate.Approved
AtropineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Atropine.Approved, Vet Approved
AzelastineThe metabolism of Azelastine can be decreased when combined with Darifenacin.Approved
BenactyzineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Darifenacin.Approved
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Darifenacin.Approved
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Darifenacin.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Darifenacin.Approved, Withdrawn
BetaxololThe metabolism of Darifenacin can be decreased when combined with Betaxolol.Approved
BexaroteneThe serum concentration of Darifenacin can be decreased when it is combined with Bexarotene.Approved, Investigational
BezitramideThe risk or severity of adverse effects can be increased when Darifenacin is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Darifenacin is combined with Biperiden.Approved
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Darifenacin.Approved
BoceprevirThe metabolism of Darifenacin can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Darifenacin can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Darifenacin can be decreased when it is combined with Bosentan.Approved, Investigational
Botulinum Toxin Type ADarifenacin may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BDarifenacin may increase the anticholinergic activities of Botulinum Toxin Type B.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Darifenacin.Approved
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Darifenacin.Approved
BufuralolThe metabolism of Bufuralol can be decreased when combined with Darifenacin.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Darifenacin.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Darifenacin.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Darifenacin can be decreased when combined with Bupropion.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Darifenacin.Approved, Investigational
ButorphanolThe risk or severity of adverse effects can be increased when Darifenacin is combined with Butorphanol.Approved, Illicit, Vet Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Darifenacin.Approved
CaptoprilThe metabolism of Captopril can be decreased when combined with Darifenacin.Approved
CarbamazepineThe metabolism of Darifenacin can be increased when combined with Carbamazepine.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Darifenacin is combined with Carfentanil.Illicit, Vet Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Darifenacin.Approved
CarteololThe metabolism of Carteolol can be decreased when combined with Darifenacin.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Darifenacin.Approved, Investigational
CelecoxibThe metabolism of Darifenacin can be decreased when combined with Celecoxib.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Darifenacin.Approved, Vet Approved
CeritinibThe serum concentration of Darifenacin can be increased when it is combined with Ceritinib.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Darifenacin.Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Darifenacin.Approved, Illicit
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Darifenacin.Approved, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Darifenacin.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Darifenacin.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Chlorphenoxamine.Withdrawn
ChlorpromazineThe metabolism of Darifenacin can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Darifenacin.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Darifenacin.Approved
CholecalciferolThe metabolism of Darifenacin can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilostazolThe metabolism of Cilostazol can be decreased when combined with Darifenacin.Approved
CimetidineThe metabolism of Darifenacin can be decreased when combined with Cimetidine.Approved
CimetropiumDarifenacin may increase the anticholinergic activities of Cimetropium.Experimental
CinacalcetThe metabolism of Darifenacin can be decreased when combined with Cinacalcet.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Darifenacin.Approved
CitalopramThe metabolism of Darifenacin can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Darifenacin can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Darifenacin can be decreased when combined with Clemastine.Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Darifenacin.Approved
ClobazamThe metabolism of Darifenacin can be decreased when combined with Clobazam.Approved, Illicit
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Darifenacin.Approved, Vet Approved
ClonidineThe metabolism of Clonidine can be decreased when combined with Darifenacin.Approved
ClotrimazoleThe metabolism of Darifenacin can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Darifenacin can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Darifenacin can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Darifenacin can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Darifenacin.Approved, Illicit
ConivaptanThe serum concentration of Darifenacin can be increased when it is combined with Conivaptan.Approved, Investigational
CoumaphosThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Coumaphos.Vet Approved
CrizotinibThe metabolism of Darifenacin can be decreased when combined with Crizotinib.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Darifenacin.Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Darifenacin is combined with Cyclopentolate.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Darifenacin.Approved, Investigational
CyclosporineThe metabolism of Darifenacin can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Darifenacin can be decreased when it is combined with Dabrafenib.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Darifenacin.Approved
DarunavirThe serum concentration of Darifenacin can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Darifenacin.Approved
DasatinibThe serum concentration of Darifenacin can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Darifenacin.Approved
DecamethoniumThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Decamethonium.Approved
DeferasiroxThe serum concentration of Darifenacin can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Darifenacin can be decreased when combined with Delavirdine.Approved
DemecariumThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Demecarium.Approved
DesipramineThe metabolism of Desipramine can be decreased when combined with Darifenacin.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Darifenacin can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexetimideThe risk or severity of adverse effects can be increased when Darifenacin is combined with Dexetimide.Withdrawn
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Darifenacin.Approved, Illicit, Withdrawn
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Darifenacin.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Darifenacin.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Darifenacin.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Darifenacin is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Darifenacin is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Dezocine.Approved
DichlorvosThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Dicyclomine.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Darifenacin.Approved, Illicit
DihydroergotamineThe metabolism of Darifenacin can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Darifenacin can be decreased when combined with Diltiazem.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Darifenacin.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Darifenacin is combined with Diphenoxylate.Approved, Illicit
DolasetronThe metabolism of Dolasetron can be decreased when combined with Darifenacin.Approved
DomperidoneThe metabolism of Domperidone can be decreased when combined with Darifenacin.Approved, Investigational, Vet Approved
DonepezilThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Donepezil.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Darifenacin.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Darifenacin.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Darifenacin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Darifenacin.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Darifenacin.Approved, Investigational
DoxycyclineThe metabolism of Darifenacin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Darifenacin is combined with DPDPE.Investigational
DronabinolDarifenacin may increase the tachycardic activities of Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Darifenacin can be decreased when combined with Dronedarone.Approved
DuloxetineThe metabolism of Darifenacin can be decreased when combined with Duloxetine.Approved
EchothiophateThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Edrophonium.Approved
EfavirenzThe serum concentration of Darifenacin can be decreased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Darifenacin.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Darifenacin.Approved
EluxadolineDarifenacin may increase the constipating activities of Eluxadoline.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Darifenacin.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Darifenacin.Investigational
EnzalutamideThe serum concentration of Darifenacin can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Darifenacin.Approved, Investigational
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Darifenacin.Approved, Investigational
ErythromycinThe metabolism of Darifenacin can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Darifenacin.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Darifenacin can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Darifenacin.Investigational
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Darifenacin.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Darifenacin.Approved, Illicit
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Darifenacin.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Darifenacin can be decreased when it is combined with Etravirine.Approved
FentanylThe risk or severity of adverse effects can be increased when Darifenacin is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Darifenacin.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Darifenacin.Approved, Investigational
FlecainideThe metabolism of Flecainide can be decreased when combined with Darifenacin.Approved, Withdrawn
FluconazoleThe metabolism of Darifenacin can be decreased when combined with Fluconazole.Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Darifenacin.Approved
FluoxetineThe metabolism of Darifenacin can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Darifenacin.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Darifenacin.Approved
FluvoxamineThe metabolism of Darifenacin can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Darifenacin.Approved, Investigational
FosamprenavirThe metabolism of Darifenacin can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Darifenacin can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Darifenacin can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Darifenacin can be increased when it is combined with Fusidic Acid.Approved
GalantamineThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Darifenacin.Approved
GefitinibThe metabolism of Gefitinib can be decreased when combined with Darifenacin.Approved, Investigational
Ginkgo bilobaThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Ginkgo biloba.Approved, Nutraceutical
Glucagon recombinantThe risk or severity of adverse effects can be increased when Darifenacin is combined with Glucagon recombinant.Approved
GlycopyrroniumDarifenacin may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
GranisetronThe metabolism of Granisetron can be decreased when combined with Darifenacin.Approved, Investigational
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Darifenacin.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Darifenacin.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Darifenacin.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Darifenacin is combined with Hexamethonium.Experimental
HomatropineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Huperzine A.Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Darifenacin.Approved, Vet Approved
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Darifenacin.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Darifenacin.Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Darifenacin.Approved, Illicit
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Darifenacin.Approved
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Darifenacin.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Darifenacin.Approved
IdelalisibThe serum concentration of Darifenacin can be increased when it is combined with Idelalisib.Approved
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Darifenacin.Approved
ImatinibThe metabolism of Darifenacin can be decreased when combined with Imatinib.Approved
ImipramineThe metabolism of Darifenacin can be decreased when combined with Imipramine.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Darifenacin.Approved
IndinavirThe metabolism of Darifenacin can be decreased when combined with Indinavir.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Darifenacin.Approved
IsavuconazoniumThe metabolism of Darifenacin can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Isoflurophate.Approved, Withdrawn
IsoniazidThe metabolism of Darifenacin can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Darifenacin can be decreased when combined with Isradipine.Approved
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Darifenacin.Investigational
ItraconazoleThe metabolism of Darifenacin can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Darifenacin can be increased when it is combined with Ivacaftor.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Darifenacin.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Darifenacin is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Darifenacin can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe metabolism of Labetalol can be decreased when combined with Darifenacin.Approved
LevodopaThe metabolism of Levodopa can be decreased when combined with Darifenacin.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Darifenacin is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Darifenacin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Darifenacin is combined with Levorphanol.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Darifenacin.Approved, Vet Approved
LisurideThe metabolism of Lisuride can be decreased when combined with Darifenacin.Approved
LofentanilThe risk or severity of adverse effects can be increased when Darifenacin is combined with Lofentanil.Illicit
LomustineThe metabolism of Lomustine can be decreased when combined with Darifenacin.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Darifenacin.Approved
LopinavirThe metabolism of Darifenacin can be decreased when combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Darifenacin.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Darifenacin.Approved
LovastatinThe metabolism of Darifenacin can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Darifenacin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Darifenacin can be increased when combined with Lumacaftor.Approved
LumefantrineThe metabolism of Darifenacin can be decreased when combined with Lumefantrine.Approved
MalathionThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Malathion.Approved, Investigational
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Darifenacin.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Mecamylamine.Approved
MefloquineThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Mefloquine.Approved
MemantineThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Memantine.Approved, Investigational
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Darifenacin.Investigational, Withdrawn
MequitazineThe metabolism of Mequitazine can be decreased when combined with Darifenacin.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Darifenacin.Approved
MethadoneThe metabolism of Darifenacin can be decreased when combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Darifenacin is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Darifenacin.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Methantheline.Approved
MethotrimeprazineThe metabolism of Darifenacin can be decreased when combined with Methotrimeprazine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Darifenacin.Approved, Vet Approved
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Darifenacin.Approved
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Darifenacin.Approved, Investigational
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Darifenacin.Approved, Illicit, Withdrawn
MetixeneThe risk or severity of adverse effects can be increased when Darifenacin is combined with Metixene.Approved
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Darifenacin.Approved, Investigational
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Darifenacin.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Darifenacin.Approved, Investigational
MexiletineThe metabolism of Mexiletine can be decreased when combined with Darifenacin.Approved
MianserinMianserin may increase the anticholinergic activities of Darifenacin.Approved
MifepristoneThe serum concentration of Darifenacin can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Minaprine.Approved
MirabegronThe risk or severity of adverse effects can be increased when Darifenacin is combined with Mirabegron.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Darifenacin.Approved
MitotaneThe serum concentration of Darifenacin can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Darifenacin.Approved
ModafinilThe serum concentration of Darifenacin can be decreased when it is combined with Modafinil.Approved, Investigational
MorphineThe metabolism of Morphine can be decreased when combined with Darifenacin.Approved, Investigational
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Darifenacin is combined with N-butylscopolammonium bromide.Vet Approved
NabiloneDarifenacin may increase the tachycardic activities of Nabilone.Approved, Investigational
NafcillinThe serum concentration of Darifenacin can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Nalbuphine.Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Darifenacin.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Darifenacin.Approved, Investigational
NefazodoneThe metabolism of Darifenacin can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Darifenacin can be decreased when combined with Nelfinavir.Approved
NeostigmineThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Darifenacin can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Darifenacin can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Nicardipine can be decreased when combined with Darifenacin.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Darifenacin.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Darifenacin.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Darifenacin.Approved
NilotinibThe metabolism of Darifenacin can be decreased when combined with Nilotinib.Approved, Investigational
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Darifenacin.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Darifenacin is combined with Normethadone.Approved, Illicit
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Darifenacin.Approved
NVA237The risk or severity of adverse effects can be increased when Darifenacin is combined with NVA237.Investigational
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Darifenacin.Approved, Investigational
OlaparibThe metabolism of Darifenacin can be decreased when combined with Olaparib.Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Darifenacin.Approved
OpiumThe risk or severity of adverse effects can be increased when Darifenacin is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Orphenadrine.Approved
OsimertinibThe serum concentration of Darifenacin can be increased when it is combined with Osimertinib.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Darifenacin is combined with Oxybutynin.Approved, Investigational
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Darifenacin.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Darifenacin.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Darifenacin.Approved
PalbociclibThe serum concentration of Darifenacin can be increased when it is combined with Palbociclib.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Darifenacin.Approved, Investigational
PancuroniumThe risk or severity of adverse effects can be increased when Darifenacin is combined with Pancuronium.Approved
PanobinostatThe serum concentration of Darifenacin can be increased when it is combined with Panobinostat.Approved, Investigational
ParoxetineThe metabolism of Darifenacin can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe metabolism of Pazopanib can be decreased when combined with Darifenacin.Approved
Peginterferon alfa-2bThe serum concentration of Darifenacin can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentamidineThe metabolism of Pentamidine can be decreased when combined with Darifenacin.Approved
PentazocineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe metabolism of Darifenacin can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Darifenacin is combined with Pentolinium.Approved
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Darifenacin.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Darifenacin.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Darifenacin.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Darifenacin.Withdrawn
PhenforminThe metabolism of Phenformin can be decreased when combined with Darifenacin.Approved, Withdrawn
PhenobarbitalThe metabolism of Darifenacin can be increased when combined with Phenobarbital.Approved
PhenytoinThe metabolism of Darifenacin can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Physostigmine.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Darifenacin.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Darifenacin is combined with Pipecuronium.Approved
PiperazineThe metabolism of Piperazine can be decreased when combined with Darifenacin.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Darifenacin.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Pirenzepine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Darifenacin is combined with Piritramide.Investigational
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Darifenacin.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Darifenacin.Approved
PosaconazoleThe metabolism of Darifenacin can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium ChlorideDarifenacin may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Darifenacin.Approved, Investigational
PrimidoneThe metabolism of Darifenacin can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideThe metabolism of Procainamide can be decreased when combined with Darifenacin.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Darifenacin.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Darifenacin.Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Darifenacin.Approved, Vet Approved
PromazineThe metabolism of Darifenacin can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe metabolism of Promethazine can be decreased when combined with Darifenacin.Approved
PropafenoneThe serum concentration of Darifenacin can be increased when it is combined with Propafenone.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Propantheline.Approved
PropiverineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Propiverine.Investigational
PropofolThe metabolism of Propofol can be decreased when combined with Darifenacin.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Darifenacin.Approved, Investigational
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Darifenacin.Approved
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Darifenacin.Approved
PyridostigmineThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Pyridostigmine.Approved
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Darifenacin.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Darifenacin.Approved
QuinidineThe metabolism of Darifenacin can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Darifenacin can be decreased when combined with Quinine.Approved
RamosetronDarifenacin may increase the constipating activities of Ramosetron.Approved
RanitidineThe metabolism of Ranitidine can be decreased when combined with Darifenacin.Approved
RanolazineThe metabolism of Darifenacin can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Darifenacin is combined with Remifentanil.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Darifenacin.Approved, Withdrawn
repinotanThe metabolism of repinotan can be decreased when combined with Darifenacin.Investigational
RifabutinThe metabolism of Darifenacin can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Darifenacin can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Darifenacin can be increased when combined with Rifapentine.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Darifenacin.Approved, Investigational
RitonavirThe metabolism of Darifenacin can be decreased when combined with Ritonavir.Approved, Investigational
RivastigmineThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Rivastigmine.Approved, Investigational
RolapitantThe metabolism of Darifenacin can be decreased when combined with Rolapitant.Approved
RopiniroleThe metabolism of Darifenacin can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Darifenacin.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Darifenacin.Approved
SaquinavirThe metabolism of Darifenacin can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Darifenacin is combined with Scopolamine butylbromide.Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Darifenacin.Approved, Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Darifenacin.Approved, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Darifenacin.Approved
SildenafilThe metabolism of Darifenacin can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Darifenacin can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Darifenacin can be increased when it is combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Darifenacin.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Solifenacin.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Darifenacin.Experimental
St. John's WortThe serum concentration of Darifenacin can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Darifenacin can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Darifenacin is combined with Sufentanil.Approved, Investigational
SulfisoxazoleThe metabolism of Darifenacin can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Darifenacin.Approved
TacrineThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Tacrine.Withdrawn
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Darifenacin resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Darifenacin.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Darifenacin.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Darifenacin.Investigational, Withdrawn
TelaprevirThe metabolism of Darifenacin can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Darifenacin can be decreased when combined with Telithromycin.Approved
TerbinafineThe metabolism of Darifenacin can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Darifenacin.Withdrawn
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Darifenacin.Investigational
TetrabenazineThe metabolism of Tetrabenazine can be decreased when combined with Darifenacin.Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Darifenacin.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Darifenacin.Approved
TiclopidineThe metabolism of Darifenacin can be decreased when combined with Ticlopidine.Approved
TimololThe metabolism of Timolol can be decreased when combined with Darifenacin.Approved
TiotropiumDarifenacin may increase the anticholinergic activities of Tiotropium.Approved
TipranavirThe metabolism of Darifenacin can be decreased when combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Darifenacin can be decreased when it is combined with Tocilizumab.Approved
TolterodineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Tolterodine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Darifenacin is combined with Topiramate.Approved
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Darifenacin.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Darifenacin.Approved, Investigational
TranylcypromineThe metabolism of Darifenacin can be decreased when combined with Tranylcypromine.Approved
TrazodoneThe metabolism of Trazodone can be decreased when combined with Darifenacin.Approved, Investigational
TrichlorfonThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Darifenacin.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Darifenacin.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Darifenacin is combined with Trimethaphan.Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Darifenacin.Approved
TropicamideThe risk or severity of adverse effects can be increased when Darifenacin is combined with Tropicamide.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Darifenacin.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Darifenacin is combined with Tubocurarine.Approved
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Darifenacin.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Darifenacin is combined with Vecuronium.Approved
VenlafaxineThe metabolism of Darifenacin can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Darifenacin can be decreased when combined with Verapamil.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Darifenacin.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Darifenacin.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Darifenacin.Approved, Investigational
VoriconazoleThe metabolism of Darifenacin can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Darifenacin.Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Darifenacin.Approved, Vet Approved
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Darifenacin.Approved
ZiprasidoneThe metabolism of Darifenacin can be decreased when combined with Ziprasidone.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Darifenacin.Approved
ZuclopenthixolThe metabolism of Zuclopenthixol can be decreased when combined with Darifenacin.Approved, Investigational
Food Interactions
  • Take without regard to meals.
References
Synthesis Reference

Valeriano Merli, Augusto Canavesi, Paola Daverio, “Processes for preparing darifenacin hydrobromide.” U.S. Patent US20070197631, issued August 23, 2007.

US20070197631
General ReferencesNot Available
External Links
ATC CodesG04BD10
AHFS Codes
  • 86:12.00
PDB EntriesNot Available
FDA labelDownload (394 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9966
Blood Brain Barrier+0.9989
Caco-2 permeable-0.5256
P-glycoprotein substrateSubstrate0.6385
P-glycoprotein inhibitor INon-inhibitor0.6329
P-glycoprotein inhibitor IIInhibitor0.5374
Renal organic cation transporterInhibitor0.6441
CYP450 2C9 substrateNon-substrate0.8774
CYP450 2D6 substrateNon-substrate0.5946
CYP450 3A4 substrateSubstrate0.6046
CYP450 1A2 substrateNon-inhibitor0.696
CYP450 2C9 inhibitorNon-inhibitor0.8253
CYP450 2D6 inhibitorInhibitor0.5816
CYP450 2C19 inhibitorInhibitor0.5399
CYP450 3A4 inhibitorInhibitor0.5
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6168
Ames testNon AMES toxic0.7145
CarcinogenicityNon-carcinogens0.8847
BiodegradationNot ready biodegradable0.9599
Rat acute toxicity3.0008 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.907
hERG inhibition (predictor II)Inhibitor0.6703
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Novartis pharmaceuticals corp
Packagers
Dosage forms
FormRouteStrength
Tablet, film coated, extended releaseOral15 mg/1
Tablet, film coated, extended releaseOral7.5 mg/1
Tablet, extended releaseOral15 mg
Tablet, extended releaseOral15 mg/1
Tablet, extended releaseOral7.5 mg/1
Tablet, extended releaseOral7.5 mg
Prices
Unit descriptionCostUnit
Enablex 15 mg 24 Hour tablet5.22USD tablet
Enablex 7.5 mg 24 Hour tablet5.22USD tablet
Enablex 15 mg tablet5.02USD tablet
Enablex 7.5 mg tablet5.02USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2230314 No2003-06-242016-08-21Canada
CA2469702 No2010-07-062022-03-05Canada
US5096890 No1995-03-132015-03-13Us
US6106864 No1996-08-212016-08-21Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP4.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000298 mg/mLALOGPS
logP4.35ALOGPS
logP4.54ChemAxon
logS-6.2ALOGPS
pKa (Strongest Acidic)16.21ChemAxon
pKa (Strongest Basic)10.11ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area55.56 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity128.37 m3·mol-1ChemAxon
Polarizability48.54 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylmethanes
Direct ParentDiphenylmethanes
Alternative Parents
Substituents
  • Diphenylmethane
  • Phenylacetamide
  • Phenylpropylamine
  • Phenethylamine
  • Benzofuran
  • Aralkylamine
  • Alkyl aryl ether
  • N-alkylpyrrolidine
  • Pyrrolidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Primary carboxylic acid amide
  • Carboxamide group
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Bharucha AE, Ravi K, Zinsmeister AR: Comparison of selective M3 and nonselective muscarinic receptor antagonists on gastrointestinal transit and bowel habits in humans. Am J Physiol Gastrointest Liver Physiol. 2010 Jul;299(1):G215-9. doi: 10.1152/ajpgi.00072.2010. Epub 2010 Apr 15. [PubMed:20395537 ]
  2. Bozkurt TE, Sahin-Erdemli I: M(1) and M(3) muscarinic receptors are involved in the release of urinary bladder-derived relaxant factor. Pharmacol Res. 2009 May;59(5):300-5. doi: 10.1016/j.phrs.2009.01.013. Epub 2009 Feb 5. [PubMed:19416629 ]
  3. Jha S, Parsons M: Treatment of overactive bladder in the aging population: focus on darifenacin. Clin Interv Aging. 2006;1(4):309-16. [PubMed:18046909 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Jha S, Parsons M: Treatment of overactive bladder in the aging population: focus on darifenacin. Clin Interv Aging. 2006;1(4):309-16. [PubMed:18046909 ]
  2. Moriya H, Takagi Y, Nakanishi T, Hayashi M, Tani T, Hirotsu I: Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351-8. [PubMed:10374898 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Jha S, Parsons M: Treatment of overactive bladder in the aging population: focus on darifenacin. Clin Interv Aging. 2006;1(4):309-16. [PubMed:18046909 ]
  2. Moriya H, Takagi Y, Nakanishi T, Hayashi M, Tani T, Hirotsu I: Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351-8. [PubMed:10374898 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Jha S, Parsons M: Treatment of overactive bladder in the aging population: focus on darifenacin. Clin Interv Aging. 2006;1(4):309-16. [PubMed:18046909 ]
  2. Moriya H, Takagi Y, Nakanishi T, Hayashi M, Tani T, Hirotsu I: Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351-8. [PubMed:10374898 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Moriya H, Takagi Y, Nakanishi T, Hayashi M, Tani T, Hirotsu I: Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351-8. [PubMed:10374898 ]
  2. Jha S, Parsons M: Treatment of overactive bladder in the aging population: focus on darifenacin. Clin Interv Aging. 2006;1(4):309-16. [PubMed:18046909 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Skerjanec A: The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet. 2006;45(4):325-50. [PubMed:16584282 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Skerjanec A: The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet. 2006;45(4):325-50. [PubMed:16584282 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 07, 2016 02:38